KLRA Stock Chart & Stats
$18.44
--
Market closed
$18.44
--
Day’s Range― - ―
52-Week Range$15.15 - $28.23
Previous CloseN/A
VolumeN/A
Average Volume (3M)618.37K
Market Cap
$2.10B
Enterprise Value$1.95K
Total Cash (Recent Filing)$916.74M
Total Debt (Recent Filing)$10.22M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Jun 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.76
Shares Outstanding129,643,680
10 Day Avg. Volume787,917
30 Day Avg. Volume618,372
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-8.60
Price to Sales (P/S)0.00
P/FCF Ratio-25.08
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$45.00Price Target Upside144.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-4.01
Revenue Forecast (FY)N/A
KLRA FAQ
What was Kailera Therapeutics, Inc.’s price range in the past 12 months?
Kailera Therapeutics, Inc. lowest stock price was $15.15 and its highest was $28.23 in the past 12 months.
What is Kailera Therapeutics, Inc.’s market cap?
Kailera Therapeutics, Inc.’s market cap is $2.10B.
When is Kailera Therapeutics, Inc.’s upcoming earnings report date?
Kailera Therapeutics, Inc.’s upcoming earnings report date is Jun 01, 2027 which is in 267 days.
How were Kailera Therapeutics, Inc.’s earnings last quarter?
Kailera Therapeutics, Inc. released its earnings results on Aug 12, 2026. The company reported -$1.09 earnings per share for the quarter, missing the consensus estimate of -$0.897 by -$0.193.
Is Kailera Therapeutics, Inc. overvalued?
According to Wall Street analysts Kailera Therapeutics, Inc.’s price is currently Undervalued.
Does Kailera Therapeutics, Inc. pay dividends?
Kailera Therapeutics, Inc. does not currently pay dividends.
What is Kailera Therapeutics, Inc.’s EPS estimate?
Kailera Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kailera Therapeutics, Inc. have?
Kailera Therapeutics, Inc. has 129,643,680 shares outstanding.
What happened to Kailera Therapeutics, Inc.’s price movement after its last earnings report?
Kailera Therapeutics, Inc. reported an EPS of -$1.09 in its last earnings report, missing expectations of -$0.897. Following the earnings report the stock price went down -3.335%.
Which hedge fund is a major shareholder of Kailera Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KLRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kailera Therapeutics, Inc. Stock Smart Score
Company Description
Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
KLRA Stock 12 Month Forecast
Average Price Target
$45.00
▲(144.03% Upside)
Ocular Therapeutix
―
Aclaris Therapeutics
―
Trevi Therapeutics
―
Beam Therapeutics
―
Tarsus Pharmaceuticals
―
Ownership Overview
85.31% Insiders
2.93% Mutual Funds
5.94% Other Institutional Investors
1.31% Public Companies and
Individual Investors